商品名：Bonefos*, Loron*
Adsorbed on to hydroxyapatite crystals and ingested by osteoclasts. Metabolized in the cell to compounds that compete with ATP, leading to apoptosis of the cell and thus slowing the rate of bone destruction. This class of drugs may also decrease intestinal absorption of calcium and influence vitamin D3 metabolism.
Treatment of acute moderate to severe hypercalcaemia when other therapies are ineffective, or in the long-term therapy of chronic hypercalcaemia. Few reports of use in dogs and no reports of use in cats or other veterinary species. Excretion reduced in chronic renal failure; dose adjustment may be required. Aledronate is similar to clodronate but experience is limited.
劑量數字暫停提供：VetPro 的劑量改依 DRUGAPI 藥物資料庫對外的內容，DRUGAPI 目前不提供可直接計算的劑量。下方列出 DRUGAPI 的審查結論與劑量審查引用的來源；計算機可手動輸入劑量換算。
公開證據足以建立確切馬用 OSPHOS／Osphos 標籤、安全性與法規邊界，但美國與英國的活性基質表示、劑量表達、交互作用、再治療與食用動物規則不同；犬用證據僅限小型實驗模型，且無法支持通用犬貓療程。
DRUGAPI 劑量審查引用的獸醫官方標示（各標示只適用於其產品、物種與法域，不可互換）
依出現頻率分組；嚴重副作用獨立列出，臨床上需立即辨識。